{"id":757209,"date":"2023-05-10T08:05:04","date_gmt":"2023-05-10T12:05:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/"},"modified":"2023-05-10T08:05:04","modified_gmt":"2023-05-10T12:05:04","slug":"fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/","title":{"rendered":"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort"},"content":{"rendered":"

<\/p>\n

FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort<\/b><\/p>\n

TORONTO–(BUSINESS WIRE<\/a>)–
\nFSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (\u201cFSD Pharma<\/b>\u201d or the \u201cCompany<\/b>\u201d), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the completion of dosing the first cohort of patients in the Company\u2019s Phase I clinical trial of Lucid-21-302 (\u201cLucid-MS\u201d). The clinical trial (ClinicalTrials.gov Identifier: NCT05821387<\/a>), being conducted by FSD Pharma through the Company\u2019s wholly owned subsidiary Lucid Psycheceuticals, is a first-in-human study evaluating Lucid-MS, a small molecule inhibitor of hypercitrullination, as a novel drug candidate for the treatment of Multiple Sclerosis (\u201cMS\u201d).<\/p>\n

\n\u201cOur clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort,\u201d said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals. \u201cThe safety review committee has recommended to move forward with the next cohort dosing, which we are thrilled to say is expected to commence in the next few days.\u201d<\/p>\n

\nThe clinical trial is a randomized, double-blind, placebo controlled, single ascending dose (\u201cSAD\u201d) and multiple ascending dose (\u201cMAD\u201d) study with the primary outcomes evaluating the safety, tolerability, and pharmacokinetics of Lucid-MS in healthy volunteers under fed and fasted conditions. Enrollment will be comprised of five SAD cohorts and two MAD cohorts. Each SAD and MAD cohort will enroll eight participants (for a total of 56 participants) randomized to six active and two placebo groups. Participants in the active group will receive single or multiple doses of Lucid-MS. For the SAD cohort with food effect, all eight participants will receive Lucid-MS.<\/p>\n

\nLucid-MS is a patented first-in-class, New Chemical Entity (\u201cNCE\u201d) and a neuroprotective compound with a novel mechanism of action for the treatment of MS. In preclinical models, Lucid-MS has been shown to prevent myelin degradation (demyelination), a hallmark pathology feature of MS and other neurogenerative diseases characterized by damage to the myelin sheath surrounding nerve fibers in the central nervous system. Preclinical evidence has demonstrated Lucid-MS to promote functional recovery in experimental animal models of MS (https:\/\/fsdpharma.com\/our-science\/<\/a>). Based on current evidence, Lucid-MS is non-immunomodulatory agent, an important distinction in the potential for developing new, safe options for treating MS.<\/p>\n

\n

About FSD Pharma<\/b><\/p>\n

\nFSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, a proprietary ultra-micronized PEA formulation, for the treatment of inflammatory diseases. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders, and expanding this category, the Company is investigating other products addressing acute medical needs due to the abuse of drugs such as alcohol. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.<\/p>\n

Forward Looking Information<\/b><\/p>\n

\nThis press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements<\/b>“)within the meaning of applicable securities laws. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as \u201cplans\u201d, \u201cexpects\u201d, \u201cexpected\u201d, \u201cscheduled\u201d, \u201cestimates\u201d, \u201cintends\u201d, \u201canticipates\u201d, \u201chopes\u201d, \u201cplanned\u201d or \u201cbelieves\u201d, or variations of such words and phrases, or states that certain actions, events or results \u201cmay\u201d, \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d, \u201cpotentially\u201d or \u201cwill\u201d be taken, occur or be achieved. More particularly, and without limitation, this press release contains forward-looking statements contained in this press release include statements concerning the future of FSD Pharma Inc. and are based on certain assumptions that FSD Pharma has made in respect thereof as of the date of this press release. FSD Pharma cannot give any assurance that such forward-looking statements will prove to have been correct.<\/p>\n

\nSince forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it believes the expectations and material factors and assumptions reflected in these forward-looking statements are reasonable as of the date hereof, there can be no assurance that these expectations, factors and assumptions will prove to be correct and these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to a number of known and unknown risks and uncertainties including, but not limited to: the fact that the drug development efforts of both Lucid and FSD BioSciences are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates of Lucid and FSD BioSciences may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of Lucid and FSD BioSciences; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of Lucid and FSD BioSciences; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of Lucid and FSD BioSciences; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected, or impacted by COVID-19 related issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of Lucid and FSD BioSciences; and other risks. Accordingly, readers should not place undue reliance on the forward-looking statements contained in this press release, which speak only as of the date of this press release.<\/p>\n

\n

\nFurther information regarding factors that may cause actual results to differ materially are included in the Company\u2019s annual and other reports filed from time to time with the Canadian Securities Administrators on SEDAR (www.sedar.com<\/a>) and with the U.S. Securities and Exchange Commission on EDGAR (www.sec.gov<\/a>), including the Company\u2019s Annual Report on Form 20-F for the fiscal year ended December 31, 2021, under the heading \u201cRisk Factors.\u201d This list of risk factors should not be construed as exhaustive. Readers are cautioned that events or circumstances could cause results to differ materially from those predicted, forecasted or projected. The forward-looking statements contained in this document speak only as of the date of this document. FSD Pharma does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.<\/p>\n

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230510005267\/en\/<\/a><\/span><\/p>\n

\nZeeshan Saeed, Founder, President and Executive Co-Chairman of the Board, FSD Pharma Inc.
\n
Email: Zsaeed@fsdpharma.com
\n<\/a>
Telephone: (416) 854-8884<\/p>\n

\nInvestor Relations:
\n
Email: ir@fsdpharma.com<\/a>, info@fsdpharma.com
\n<\/a>
Website: www.fsdpharma.com
\n<\/a>
ClearThink
\n
Email: nyc@clearthink.capital
\n<\/a>
Telephone: (917) 658-7878<\/p>\n

KEYWORDS:<\/b> North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Neurology Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort TORONTO–(BUSINESS WIRE)– FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (\u201cFSD Pharma\u201d or the \u201cCompany\u201d), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the completion of dosing the first cohort of patients in the Company\u2019s Phase I clinical trial of Lucid-21-302 (\u201cLucid-MS\u201d). The clinical trial (ClinicalTrials.gov Identifier: NCT05821387), being conducted by FSD Pharma through the Company\u2019s wholly owned subsidiary Lucid Psycheceuticals, is a first-in-human study evaluating Lucid-MS, a … <\/p>\n

Continue reading “FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-757209","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort TORONTO–(BUSINESS WIRE)– FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (\u201cFSD Pharma\u201d or the \u201cCompany\u201d), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the completion of dosing the first cohort of patients in the Company\u2019s Phase I clinical trial of Lucid-21-302 (\u201cLucid-MS\u201d). The clinical trial (ClinicalTrials.gov Identifier: NCT05821387), being conducted by FSD Pharma through the Company\u2019s wholly owned subsidiary Lucid Psycheceuticals, is a first-in-human study evaluating Lucid-MS, a … Continue reading "FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-10T12:05:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230510005267r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort\",\"datePublished\":\"2023-05-10T12:05:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/\"},\"wordCount\":1306,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230510005267r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/\",\"name\":\"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230510005267r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-05-10T12:05:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230510005267r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230510005267r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/","og_locale":"en_US","og_type":"article","og_title":"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort - Market Newsdesk","og_description":"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort TORONTO–(BUSINESS WIRE)– FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (\u201cFSD Pharma\u201d or the \u201cCompany\u201d), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the completion of dosing the first cohort of patients in the Company\u2019s Phase I clinical trial of Lucid-21-302 (\u201cLucid-MS\u201d). The clinical trial (ClinicalTrials.gov Identifier: NCT05821387), being conducted by FSD Pharma through the Company\u2019s wholly owned subsidiary Lucid Psycheceuticals, is a first-in-human study evaluating Lucid-MS, a … Continue reading \"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-10T12:05:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230510005267r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort","datePublished":"2023-05-10T12:05:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/"},"wordCount":1306,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230510005267r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/","name":"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230510005267r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-05-10T12:05:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230510005267r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230510005267r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/757209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=757209"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/757209\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=757209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=757209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=757209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}